Drug Profile

CC 6166

Alternative Names: CC-6166

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celgene Corporation
Developer Celgene Corporation; Drugs for Neglected Diseases Initiative Foundation
Class Anthelmintics; Eye disorder therapies; Skin disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2024 No recent reports of development identified for preclinical development in Onchocerciasis in USA
01 Dec 2019 Preclinical trials in Onchocerciasis in USA, before December 2019 (Drugs for Neglected Diseases Initiative Foundation pipeline, December 2019)
24 Sep 2014 Celgene Corporation and Drugs for Neglected Diseases Initiative Foundation expands research agreement to identify, optimise and co-develop Parasitic infections therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com